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Abstract 
Background: Systemic infections can influence the course of multiple sclerosis (MS), especially by driving recurrent 
acute episodes. The question whether the infection enhances tissue damage is of great clinical importance and can-
not easily be assessed in clinical trials. Here, we investigated the effects of a systemic infection with Escherichia coli, a 
Gram-negative bacterium frequently causing urinary tract infections, on the clinical course as well as on neurodegen-
eration in experimental autoimmune encephalomyelitis (EAE), an animal model of MS.
Methods: Rats were immunized with myelin oligodendrocyte glycoprotein (MOG1–125) and challenged intraperi-
toneally with live E. coli K1 in the preclinical or in the clinical phase of the disease. To ensure the survival of animals, 
antibiotic treatment with ceftriaxone was initiated 36 h after the infection and continued for 3 consecutive days.
Results: Systemic infection with E. coli did not influence the onset of clinical EAE symptoms or disease severity. 
Analysis of the optic nerve and retinal ganglion cells revealed no significant changes in the extent of inflammatory 
infiltrates, demyelination and neurodegeneration after E. coli infection.
Conclusions: We could not confirm the detrimental effect of lipopolysaccharide-induced systemic inflammation, a 
model frequently used to mimic the bacterial infection, previously observed in animal models of MS. Our results indi-
cate that the effect of an acute E. coli infection on the course of MS is less pronounced than suspected and underline 
the need for adequate models to test the role of systemic infections in the pathogenesis of MS.
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Background
Multiple sclerosis (MS) is the most frequent inflam-
matory disease of the central nervous system that often 
manifests with acute optic neuritis. The cause of MS is 
not known, but several factors have been shown to be 
associated with the risk of developing this disease includ-
ing vitamins [1], smoking [2], genetic factors [3, 4], and 
infections [5]. A link between the first clinical attack or 
relapses in MS and infections has been proposed on the 
basis of epidemiological studies [6]. There is a grow-
ing body of evidence that the onset and progression of 
MS is influenced by systemic bacterial infections. In 
MS patients, resolution of neurological symptoms that 
occurred during an infection is often incomplete [7, 8]. 
Whether this phenomenon is a consequence of truly 
aggravated neurodegeneration during the systemic infec-
tion is a question of great clinical importance.
In the majority of experimental studies in this area, 
lipopolysaccharide (LPS), a cell wall component of 
Gram-negative bacteria with strong immunostimu-
latory properties, has been used to induce systemic 
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inflammation. Systemic treatment of animals with LPS 
has been shown to promote relapses [9] and to enhance 
neurodegeneration in experimental models of MS [10]. 
Although frequently used for this purpose in animal 
models, LPS-induced inflammation does not accurately 
mimic a systemic infection with viable bacteria [11, 12]. 
Only few studies in humans or animal models dem-
onstrated an exacerbating effect of an acute infection 
with Gram-negative bacteria on the disease course of 
MS and EAE [13–15]. Here, the upper respiratory tract 
pathogen Clamydia pneumoniae is the most thoroughly 
investigated candidate. However, a large number of 
MS patients suffers from urinary bladder dysfunction, 
which in turn leads to urinary tract infections (UTIs) 
[16] and results in significant morbidity and impair-
ment in quality of life. Escherichia coli (E. coli) is a 
Gram-negative bacterium and the most common cause 
of UTI in MS patients. In the present study, we investi-
gated the impact of a systemic E. coli infection during 
the preclinical and clinical phase of experimental auto-
immune encephalomyelitis (EAE), an animal model of 
MS induced by immunization with myelin oligodendro-
cyte glycoprotein (MOG) in female Brown Norway rats, 
which shows a progressive disease course without any 
definite form of remission. We have previously demon-
strated that this model strongly reflects the neurodegen-
erative aspects of MS. 12–14  days after immunization 
with MOG, more than 90% of affected animals develop 
acute optic neuritis, which leads to acute axonal degen-
eration of the optic nerve and consecutive apoptosis of 
retinal ganglion cells (RGCs) [17–19]. In contrast, the 
amount of spinal cord lesions shows certain variability 
in this model [20–22].
Methods
Rats
Female Brown Norway rats, 8–10  weeks of age, were 
used in all experiments. Animals were obtained from 
Charles River (Sulzfeld; Germany) and kept under envi-
ronmentally controlled and pathogen-free conditions. 
All experiments involving animal use were performed 
in accordance with the relevant laws and institutional 
guidelines. All animal experiments were approved by 
the Animal Care Committee of the University Hospital 
of Göttingen, Germany, and by the Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmit-
telsicherheit (LAVES), Braunschweig, Lower Saxony; 
Germany.
Retrograde labelling of RGCs
For retrograde labelling of retinal ganglion cells, rats were 
anesthetized by intraperitoneal injection of ketamine 
(Ketanest 10; 0.95 ml/kg; Atarost, Twistringen; Germany) 
and xylazine 2% (0.25  ml/kg; Albrecht, Aulendorf; Ger-
many) and positioned in a stereotaxic frame. The skin 
was incised mediosagittaly, and holes were drilled into 
the skull above each superior colliculus (6.8  mm dorsal 
and 2  mm lateral from bregma). 2  µl of the fluorescent 
dye Fluoro-Gold (5% in distilled water; Fluorochrome, 
Englewood, CO, USA) were injected into both superior 
colliculi using a 10 µl Hamilton syringe.
Induction of EAE and infection with E. coli
Rats were anesthetized by inhalation anaesthesia with 
isoflurane and injected subcutaneously at the base of 
the tail with a total volume of 200 µl inoculum, contain-
ing 50 µg recombinant rat MOGIgd (Kindly provided by 
C. Stadelmann, Department of Neuropathology, Göttin-
gen; Germany) in saline emulsified (1:1) with complete 
Freund’s adjuvant (CFA; Sigma-Aldrich, St. Louis, MO, 
USA) containing 200 µg heat-inactivated Mycobacterium 
tuberculosis (strain H 37 RA; Difco Laboratories, Detroit, 
MI, USA). Immunized animals were randomly assigned 
into four different groups. The animals were infected 
intraperitoneally with 106 colony-forming units (CFU) 
E. coli K1 (originally isolated from the cerebrospinal 
fluid of a child with meningitis; gift G. Zysk, Düsseldorf; 
Germany) in 400  µl 0.9% saline (B. Braun, Melsungen; 
Germany) either on day 7 post immunization (“early 
infection” group; Figure  1a) or on day one of clinical 
manifestation of EAE (“late infection” group; Figure 1b). 
Control rats received an intraperitoneal injection of an 
equal volume of saline.
The infection time point 7  days after immunization 
was chosen to elucidate whether an infection during 
the asymptomatic phase could modulate the time point 
of disease onset in MOG-EAE. The number of animals 
in this experiment used for analysis was 28 (n  =  15, 
“early infection”; n  =  13, control group) excluding the 
animals which died after E. coli infection or were sacri-
ficed for ethical reasons. To mimic the clinical situation 
in MS patients, animals were infected on day one of EAE 
(“late infection” group). Here, we addressed the question 
whether the infection aggravates the clinical symptoms of 
EAE when it occurs in the clinical phase of the disease. 
The number of animals included in this experiment used 
for analysis was 29 (n = 15, “late infection”; n = 14, con-
trol group). Data of animals that died as a consequence of 
the E. coli infection were not included in the analysis.
To ensure the survival of E. coli-infected animals, anti-
biotic treatment was started 36  h after the infection in 
both groups. All animals received 100  mg/kg ceftriax-
one (Hikma pharma; Klein-Winternheim; Germany) 
twice daily for 3 consecutive days. To confirm the sys-
temic infection in the “late infection” group, blood sam-
ples were collected from the tail vein under inhalation 
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anaesthesia with isoflurane 24 h after the infection (n = 8 
in each group). Bacterial concentrations in blood were 
determined by quantitative plating of blood samples 
on blood agar plates followed by incubation for 24  h at 
37°C. The bacterial detection limit was 100 colony form-
ing units (CFU)/ml. Animals were followed until day 8 
after the clinical manifestation of the disease (EAE d8) 
in the “early infection” and the “late infection” experi-
ment or until day 21 post immunization in case of clini-
cally healthy animals in the “early infection” experiment. 
The rationale for the study end point at day 8 of EAE lies 
in our previous studies in this animal model showing a 
gradual neurodegeneration with significant reduction of 
RGCs until day 8 of EAE. No further substantial changes 
neither in RGCs density nor in the histopathological 
changes of the optic nerve were observed beyond this 
time point when compared to day 21 of EAE [17, 18].
Clinical evaluation
Rats were scored for clinical signs of EAE and weighed 
daily. Clinical signs were scored as follows: grade 0, no 
symptoms; grade 0.5, distal paresis of the tail; grade 1, 
complete tail paralysis; grade 1.5, paresis of the tail and 
mild hind limb paresis; grade 2.0, unilateral severe hind 
limb paresis; grade 2.5, bilateral severe hind limb paresis; 
grade 3.0, complete bilateral hind limb paralysis; grade 
3.5, complete bilateral hind limb paralysis and paresis of 
one front limb; grade 4, complete paralysis (tetraplegia), 
moribund state, or death.
Histopathology and immunohistochemistry
Histopathological evaluations were performed on para-
formaldehyde-fixed, paraffin-embedded 2 µm-thick slices 
of the optic nerves (ONs). Luxol Fast Blue staining was 
performed to assess demyelination. Photographs of ver-
tical cross sections were taken using an AxioCam MR 
Microscopy camera (Zeiss, Göttingen; Germany). The 
images were processed using Zeiss AxioVision 4.2 soft-
ware to evaluate the demyelinated area as a percentage of 
the whole optic nerve cross-section. Immunohistochem-
istry was performed on paraffin-embedded ON cross-
sections representing three different levels of an optic 
nerve. ED1 macrophages/activated microglia (MCA341R 
diluted 1:500; Serotec, Oxford; UK) were detected in 
cross-sections using avidin–biotin detection. Spleen sec-
tions served as positive control for ED1 staining. ED1-
positive cells were evaluated using the following score: 
0, no labelled cells; 1, a few ED1-positive cells (number 
countable, infiltration of less than 10% of the ON cross-
section area); 2, infiltration of less than 10% of the ON 
cross-section area with ED1 positive cells in at least one 
of the three cross-sections of an ON, number of ED1-
positive cells not countable; 3, infiltration of 10–50% of 
the ON cross-section area with labelled ED1-positive 
cells in at least in one of three cross-sections of an ON; 
4, infiltration of 50–80% area of the ON cross-section 
area in at least one of the three cross-sections of an ON; 
5, infiltration of more than 80% of the ON cross-section 
area in at least one of the three cross-sections of an ON. 
Bielschowsky’s silver impregnation was performed on 
2  µm-thick cross-section slices of the ON to access the 
axonal density on the ON cross-sections. The density of 
axons in each ON was measured semi-quantitatively in 
at least nine standardized microscopic fields for each ON 
by using a 25 points grid system. Mean axon density was 
calculated for each ON.
Figure 1 Experimental design. Fluoro-Gold (FG) injection was performed 2 weeks prior to MOG immunization. a In the early infection group, intra-
peritoneal injection with E. coli or saline was performed on day (D) seven post immunization followed by antibiotic treatment (AB) for 3 consecutive 
days. Day 12–17 was the usual time for clinical onset of the disease. Animals were followed until day 8 of EAE or day 21 post immunization in case of 
clinically healthy animals. b In the late infection group intraperitoneal injection with E. coli or saline was performed in animals on the day of clinical 
manifestation of EAE. Animals were followed until day 8 of EAE. Tissue was harvested from the optic nerve for histopathological analysis, retinas 
were flat-mounted for quantification of retinal ganglion cells.
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Quantification of RGC density
At day 8 of MOG-EAE, retinas were dissected, flat-
mounted on glass slides, and examined by fluores-
cence microscopy (Zeiss Axioplan 2) using a DAPI filter 
(315/395 nm). RGC densities were determined by count-
ing labelled cells in three areas per retinal quadrant at 
three different eccentricities of 1/6, 3/6, and 5/6 of the 
retinal radius. Cell counts were performed by two inde-
pendent investigators following a blinded protocol.
Statistics
Data presented here are the cumulative results of three 
independent experiments and presented as mean ± SEM. 
Student’s t test (parametric analysis) was used to com-
pare RGC densities, demyelination and axonal densities 
within the ONs between two groups. For the comparison 
of bacterial concentrations, ED1 scores, and mean clini-
cal scores of EAE between two groups (nonparametric 
analysis), the Mann–Whitney U-test was used. A P value 
(P) ≤0.05 was considered statistically significant.
Results
Intraperitoneal injection of E. coli leads to systemic 
infection with weight loss or bacteraemia
E. coli infection was either performed on day 7 post 
immunization (“early infection”) or on day 1 of clinical 
EAE (“late infection”). In the “early infection” experiment, 
animals infected with E. coli showed a significant weight 
loss after the infection whereas animals in the control 
group did not lose weight (P < 0.001; Figure 2a). Infected 
animals recovered their weight after the antibiotic treat-
ment had been started. In contrast, in the “late infection” 
experiment, animals infected with E. coli did not show 
any significant difference in weight loss compared to 
the control group (P = 0.69; Figure 2b). This is probably 
due to the fact that during the clinical disease course of 
EAE both infected and control groups lost their weight 
rapidly. To confirm the systemic infection, E. coli con-
centrations were determined in blood samples collected 
24  h after the infection. Animals infected with E. coli 
showed high bacterial counts in blood (Log10 3.64 CFU/
ml ± 3.32), whereas no bacteria were detected in blood 
of control animals, which received saline instead of the 
bacterial inoculum. The overall animal mortality after E. 
coli infection was around 20%.
E. coli infection has no impact on onset and severity 
of clinical symptoms in MOG‑EAE
In the “early infection” experiment, 7 out of 15 E. coli 
infected animals showed clinical disease symptoms 
related to the spinal cord lesions, which did not differ 
much from the control, where 7 out of 13 animals devel-
oped clinical score of EAE. In contrast, the incidence of 
optic neuritis in “early infection” experiment was 87% in 
animals infected with E. coli and 92% in control group. 
The mean clinical score of infected animals and con-
trol animals, at the end of the experiments was not sig-
nificantly different [0.9 ±  0.35 (n =  15) vs. 1.04 ±  0.39 
(n = 13); P = 0.8; Figure 3a]. Also the mean time point 
of clinical onset of EAE was similar in both groups 
(14.17  ±  0.48  days post immunization in the infection 
group and 13.50 ±  0.62  days post immunization in the 
control group; P = 0.41).
In the “late infection” experiment, infection was 
induced only in animals, which showed clinical sign of 
EAE. The incidence of optic neuritis was 100% in both 
the animal groups. In this experiment, we observed that 
E. coli infection performed on day 1 of clinical onset of 
the disease also did not substantially modulate the course 
of EAE. Here, the mean clinical score at the end of the 
experiment was not significantly different between the 
group infected with E. coli and the respective control 
group [2.47  ±  0.22 (n  =  15) vs. 2.71  ±  0.19 (n  =  14); 
P = 0.51; Figure 3b].
Figure 2 Comparison of weight loss during the course of the experiments; a represent the weight curve in the animals infected on day 7 post 
immunization along with their control (early infection group). b represent the weight curve of the group of animals, when infection was performed 
on the day of clinical onset of the disease (late infection group) with their respective control.
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E. coli infection does not influence demyelination, 
inflammatory infiltration and axonal density of the optic 
nerve
In optic nerves evaluated histopathologically at the end 
of the experiment, the extent of demyelination was simi-
lar in animals infected with E. coli on day 7 post immuni-
zation and the respective control animals [62.90 ± 9.43% 
(n = 15) vs. 79.18 ± 8.06% (n = 13); P = 0.20; Figure 4a, 
b, g]. Analysis of inflammatory infiltrates by ED1 stain-
ing also revealed no significant difference between the 
infection group and the control group in the “early infec-
tion” experiment [2.84  ±  0.39 (n  =  15) vs. 3.45  ±  0.3 
(n  =  13) in the control group; P  =  0.50; Figure  4c, d, 
h]. Bielschowsky silver impregnation was performed to 
assess the axonal density of the ON. The axonal loss in 
infected animals and control animals did not differ signif-
icantly [66 ± 7.64% (n = 15) vs. 82.19 ± 5.69% (n = 13); 
P = 0.10; Figure 4e, f, i].
In the “late infection” experiment, we also did not 
find any effect of E. coli infection on inflammatory infil-
tration [3.94 ±  0.24 (n =  15) in the infection group vs. 
3.83 ± 0.26 (n = 14) in the control group; P = 0.74; Fig-
ure 5b] or demyelination [77.06 ± 5.77% (n = 15) in the 
infection group vs. 72.87 ±  6.46% (n =  14) in the con-
trol group; P = 0.63; Figure 5a] of the optic nerve at the 
end of the experiment. Moreover, we did not find any 
difference in axonal density. The extent of axonal loss 
was 71.84 ±  5.03% (n =  15) in the infection group and 
70.07 ±  5.39% (n =  14) in the control group (P =  0.81; 
Figure 5c).
E. coli infection does not affect neuronal viability
To evaluate the impact of E. coli infection on neuronal 
damage in MOG-EAE, numbers of surviving RGCs were 
counted on Fluoro-Gold-labeled retinal flat mounts. 
In accordance with the histopathological changes in 
the ON, analysis of RGC density did not reveal any sig-
nificant differences between infected animals and the 
respective control animals both in the “early infection” 
experiment [1,411 ±  88 vs. 1,248 ±  69/mm2; P =  0.15; 
Figure 4j, (n = 25 each)] and the “late infection” experi-
ment [967  ±  33 vs. 1,116  ±  78/mm2; P  =  0.08; Fig-
ure 5d, (n = 16 each)]. For RGC counts ‘‘n’’ indicate the 
number of eyes used for quantification. RGC counts in 
both experiments were significantly lower than those 
of healthy control animals in our previous studies 
(2,567 ± 89; mean ± SEM) [23], indicating a loss of RGCs 
in infected and non-infected animals.
Discussion and conclusions
There is a growing body of evidence that the onset and 
progression of MS is influenced by systemic infections 
caused by bacteria or viruses. Bacterial infections can 
aggravate neurological symptoms, which remain even 
after the infection is resolved, while some appears to be 
protective [24]. A better understanding of the mecha-
nisms underlying these phenomena would be an essential 
step for a rational treatment of infections in MS patients. 
In spite of the rising interest in the field linking infection 
and MS, only few studies examined the impact of real 
systemic infections with viable bacteria in animal models 
of MS. In the present study, we investigated whether sys-
temic infection with E. coli, a Gram-negative bacterium 
frequently causing urinary tract infection, has a disease-
modulating effect on EAE.
Clinical as well as experimental data indicate the pre-
clinical phase of MS to be an “at risk” period with the 
greatest susceptibility to infections [25, 26]. Systemic 
infection with Streptococcus pneumoniae 7  days after 
immunization with MOG aggravated EAE symptoms in 
mice, whereas the severity of EAE symptoms was unal-
tered in mice infected 2  days before or 21  days after 
Figure 3 Comparison of clinical course of the disease: the mean clinical score represents the neurological deficit based on spinal cord lesion. a rep-
resent the clinical course of the disease in the animals infected on day 7 post immunization (early infection group). b represent the clinical course of 
the disease when infection was performed on the day of clinical onset of the disease (late infection group). Data are shown as mean ± SEM of the 
daily score.
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MOG-immunization [27]. For this reason, in our study, 
animals were infected at day 7 post immunization corre-
sponding to the induction phase of EAE. Intraperitoneal 
injection of E. coli induced weight loss in EAE animals 
indicating severe systemic infection and sickness behav-
ior in animals. However, systemic E. coli infection during 
the latent phase of EAE did not influence the time point 
of onset of clinical symptoms or the disease severity of 
EAE in this model. To mimic the situation in MS patients 
at the beginning of a clinical event, animals were infected 
on the first day of onset of EAE symptoms. Despite the 
presence of high bacterial counts in the systemic circula-
tion of infected animals, the severity of EAE symptoms 
was not influenced by E. coli infection.
It is poorly understood whether systemic infec-
tions lead to tissue damage in the CNS with increased 
neurodegeneration, a major histopathological correlate 
of disability in MS patients. The results of magnetic res-
onance imaging (MRI) studies on the influence of extra 
cerebral infections on the number of contrast-enhancing 
MS lesions as a marker of disease activity are inconsist-
ent [28, 29]. Moreover, reliable markers for neurode-
generation in MS patients do not exist. For this reason, 
much of the knowledge about the interaction of systemic 
infection and autoimmunity in MS is derived from stud-
ies in EAE models. Previous histopathological analyses 
revealed that a single dose of LPS increased the inflam-
matory response and demyelination in EAE lesions [30]. 
In addition, it led to a switch in the macrophage/micro-
glia phenotype towards proinflammation increasing 
axonal damage in an EAE model [10]. In contrast, our 
histopathological analysis performed on cross-sections 
Figure 4 Optical nerve (ON) histopathology for the early infection group. a, b Representative Luxol Fast Blue-stained cross sections of ONs of an 
animal infected with E. coli (a) and an animal from the respective control group (b). Representative examples for the number of infiltrated ED1 
macrophages/activated microglia detected in the ON of an E. coli infected animal (c) and an animal from the non-infected control group (d). e, f 
Bielschowsky’s silver impregnation of an ON cross-section revealed no differences in axonal densities in a MOG immunized animal infected on day 7 
post immunization (e) compared to a non-infected respective control animal (f). j Represents the quantitative data for numbers of surviving retinal 
ganglion cells (RGCs) of the animals infected with E. coli and of the animals without infection. g, h and i represent the quantitative data for demyeli-
nation, inflammatory infiltrates and for axonal counts in both the E. coli infected and control group (n = 15 infected; n = 13 control). Bar length for 
Luxol Fast Blue, ED1, 100 µm, and for Bielschowsky’s silver impregnation = 20 µm.
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of the optic nerve did not reveal any significant increase 
in inflammatory infiltrates in the animals infected with 
E. coli either on day 7 post immunization or on day 1 
of EAE. In our study, we also did not observe any sig-
nificant differences in other histopathological hallmarks 
such as demyelination and axonal damage between ani-
mals infected with E. coli and the respective control ani-
mals. In accordance with the histopathology of the optic 
nerve, the survival of RGCs was also not significantly 
influenced by the E. coli infection.
Given the disease-modulating effect of systemic LPS in 
EAE [9, 10] our data are surprising. In accordance with 
our observations, the disease-aggravating effect of LPS 
observed in other neurodegenerative disease models 
[31, 32] could also not be confirmed in mouse models of 
Alzheimer’s and Parkinson’s disease when real systemic 
infections were induced by viable S. pneumoniae [31, 33] 
or E. coli (Schütze et al., unpublished observation).
There are several hypotheses that may explain the dis-
crepancy between the effect of LPS-induced systemic 
inflammation and systemic E. coli infection on clinical 
symptoms and neurodegeneration in EAE. The LPS doses 
applied in the studies mentioned above were very high 
in comparison to plasma endotoxin levels measured in 
patients with sepsis [34]. Consequently, the levels of the 
released pro-inflammatory cytokines (e.g. TNF-alpha, 
IL-1) in sepsis patients are much lower than those typi-
cally found after endotoxin infusion [35–37]. In-vitro 
data suggest that microglial activation and microglia-
mediated neurodegeneration depend on the dose of the 
inflammatory stimulus [38, 39]. We assume that stimula-
tion of the innate immune response in the CNS induced 
by the systemic E. coli infection in our study was less 
severe than that achieved by high doses of LPS and did 
not reach a sufficient level to induce neurodegeneration.
Treatment with the β-lactam antibiotic ceftriax-
one was initiated 36 h after the infection in our experi-
ments which stops bacterial application and terminates 
the effect of infection. Ceftriaxone has a bacteriolytic 
mode of action, thereby causing the rapid release of high 
amounts of bacterial products acting as strong stimuli of 
innate immunity [40]. Therefore, it is tempting to assume 
that an antibiotic treatment of infection may have an at 
least temporary effect on the course of EAE. The fact that 
the control group reached more severe disease scores in 
both the experiments argues against an aggravation of 
disease symptoms by E. coli infection followed by anti-
biotic treatment in the EAE model. The overall mortal-
ity of the E. coli infection with the antibiotic treatment 
protocol employed was approximately 20% in our study. 
Leaving the infection untreated would have resulted in 
an unacceptably high mortality. The temporary systemic 
infection followed by antibiotic treatment mimics the 
situation in well-treated acutely ill patients. However, the 
effect of a chronic E. coli on the course of EAE remains to 
be determined.
In conclusion, in our model of MOG-EAE neither the 
clinical course nor the neurodegeneration was aggravated 
by systemic infection with E. coli. Our results suggest 
that the effect of moderately severe adequately treated 
systemic infections by E. coli on MS is less pronounced 
than suspected. Given the lack of efficacy of clinical and 
experimental trials based on targets identified in LPS 
studies [12, 41], our data confirm the complexity of sys-
temic infections with viable bacteria compared to LPS-
induced inflammation and underline the necessity of 
adequate infection models for testing the role of systemic 
infection in the pathogenesis of MS.
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